What is William Blair’s Estimate for TRDA FY2024 Earnings?

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Investment analysts at William Blair boosted their FY2024 earnings per share estimates for Entrada Therapeutics in a research note issued on Tuesday, November 5th. William Blair analyst M. Minter now anticipates that the company will earn $1.19 per share for the year, up from their previous estimate of $0.43. The consensus estimate for Entrada Therapeutics’ current full-year earnings is $0.98 per share. William Blair also issued estimates for Entrada Therapeutics’ Q4 2024 earnings at ($0.69) EPS, Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.75) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.69) EPS and FY2025 earnings at ($2.95) EPS.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.90. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The business had revenue of $94.69 million for the quarter, compared to analyst estimates of $55.00 million.

Several other research analysts have also commented on TRDA. HC Wainwright raised their price target on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday. Oppenheimer upped their price target on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday.

Entrada Therapeutics Stock Up 3.1 %

NASDAQ:TRDA opened at $19.82 on Thursday. The firm’s 50 day moving average is $16.40 and its two-hundred day moving average is $15.68. Entrada Therapeutics has a fifty-two week low of $10.75 and a fifty-two week high of $19.95. The company has a market cap of $741.66 million, a P/E ratio of 12.47 and a beta of -0.26.

Insider Buying and Selling at Entrada Therapeutics

In other Entrada Therapeutics news, COO Nathan J. Dowden sold 1,904 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $15.07, for a total transaction of $28,693.28. Following the transaction, the chief operating officer now directly owns 125,996 shares in the company, valued at $1,898,759.72. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, insider Natarajan Sethuraman sold 2,642 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $15.09, for a total transaction of $39,867.78. Following the sale, the insider now owns 183,816 shares in the company, valued at $2,773,783.44. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Nathan J. Dowden sold 1,904 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $15.07, for a total value of $28,693.28. Following the transaction, the chief operating officer now directly owns 125,996 shares of the company’s stock, valued at $1,898,759.72. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,187 shares of company stock worth $155,947 in the last 90 days. 7.59% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. US Bancorp DE acquired a new position in shares of Entrada Therapeutics during the third quarter worth approximately $42,000. Acadian Asset Management LLC bought a new position in Entrada Therapeutics in the 1st quarter valued at about $79,000. SG Americas Securities LLC acquired a new position in Entrada Therapeutics during the 3rd quarter valued at about $156,000. Allspring Global Investments Holdings LLC raised its position in shares of Entrada Therapeutics by 427.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after buying an additional 11,965 shares in the last quarter. Finally, BayBridge Capital Group LLC bought a new position in shares of Entrada Therapeutics in the third quarter valued at approximately $464,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.